Phase I study of a herpes simplex virus type 2 (HSV-2) DNA vaccine administered to healthy, HSV-2-seronegative adults by a needle-free injection system.
about
HSV-2: in pursuit of a vaccineSynthetic DNA vaccine strategies against persistent viral infectionsNucleofection of DCs to generate Multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host.Population level impact of an imperfect prophylactic vaccine for herpes simplex virus-2Public TCR use by herpes simplex virus-2-specific human CD8 CTLs.The murine intravaginal HSV-2 challenge model for investigation of DNA vaccines.Detailed characterization of T cell responses to herpes simplex virus-2 in immune seronegative persons.High-purity preparation of HSV-2 vaccine candidate ACAM529 is immunogenic and efficacious in vivoHuman cytomegalovirus tropism for mucosal myeloid dendritic cells.Immunogenicity and efficacy of intramuscular replication-defective and subunit vaccines against herpes simplex virus type 2 in the mouse genital modelA mucosal vaccination approach for herpes simplex virus type 2.Development of an interferon-gamma ELISPOT assay to detect human T cell responses to HSV-2DNA vaccination in the skin using microneedles improves protection against influenza.Type-specific identification of anogenital herpes simplex virus infections by use of a commercially available nucleic acid amplification test.Patterns of human herpesvirus-8 oral shedding among diverse cohorts of human herpesvirus-8 seropositive persons.The challenge of developing a herpes simplex virus 2 vaccine.Herpes Simplex Vaccines: Prospects of Live-attenuated HSV Vaccines to Combat Genital and Ocular infections.Vaxfectin-adjuvanted plasmid DNA vaccine improves protection and immunogenicity in a murine model of genital herpes infectionA Vaxfectin(®)-adjuvanted HSV-2 plasmid DNA vaccine is effective for prophylactic and therapeutic use in the guinea pig model of genital herpes.Synthetic DNA vaccines: improved vaccine potency by electroporation and co-delivered genetic adjuvants.Generating protective immunity against genital herpesImmunogenicity and safety of different formulations of an adjuvanted glycoprotein D genital herpes vaccine in healthy adults: a double-blind randomized trial.HSV-2 vaccine: current status and insight into factors for developing an efficient vaccine.DNA vaccines for targeting bacterial infections.The ongoing pursuit of a prophylactic HSV vaccine.Intradermal Administration of Fractional Doses of Inactivated Poliovirus Vaccine: A Dose-Sparing Option for Polio Immunization.Active immunization against Pneumocystis carinii with p55-v3 DNA vaccine in rats.
P2860
Q22306291-D2BBA528-5B7A-4FB4-A4DA-FF79C5B316D1Q27016078-4CB9BC6A-A977-4EF7-BB6C-D17F9AD80488Q33713932-985AA53D-D663-42C6-AAAB-71BB78C10417Q33812029-50FD6FC3-3D97-4808-A590-0E7C7C1EB828Q33824488-056CA52F-B3F6-456B-B672-DFF791B1F99BQ33856067-1588F9D4-ABE0-4197-A3C7-9A9044B52629Q33881052-12D42D22-7587-4AA9-AF47-CDE20E9C95B1Q34331569-EC02CE6F-2A24-4FAA-8FFA-8E5D942ED339Q34422068-00E0C92E-7972-48DC-AE02-09C5C5BA5FFEQ34447379-83FEED21-B8D6-4EB2-91FF-5620B3F3802AQ34558350-89A81C6E-DA31-4B85-96B4-3D937D181403Q35202180-6AD8B101-38B4-45B9-B540-69C5556635C9Q36085414-2404849B-8CDC-4D52-A7D2-4DD54F8A90FEQ36363145-88A49CC6-8BD8-4781-AA82-81D4E76FFB80Q36565716-C10D4422-6079-452C-ACFC-A5145EC06BD7Q36671106-8CE64EC9-E3F7-4F9F-980D-E59D3BA260D7Q36824210-A0102067-CB01-4413-A723-1F36CE2D83A1Q37127506-70E76C0E-4051-4C57-8370-6D327A9759FDQ37253436-FF553360-F075-4EAE-ABE5-FB245DF3C2F3Q37276912-F29E5C2F-F20E-4885-8073-11B8F2C269A8Q37283993-12DBB060-605E-4524-93A7-FDE44D1C9C4DQ37514753-C230E16E-A8F3-4285-9447-EB4216BD488DQ37611796-77B22DA4-07CE-4E72-9A43-562CB14BBEA3Q37771943-DC6BC56F-99C6-412A-9736-9E69EC645C9DQ37991272-D8786DB5-4DE1-4766-A55D-D842B74AA126Q38609795-3E5B6159-E8FA-4C5A-986A-B90D94DCCB5DQ39755819-06D423ED-AD2A-4FCB-BF47-C6D69B395943
P2860
Phase I study of a herpes simplex virus type 2 (HSV-2) DNA vaccine administered to healthy, HSV-2-seronegative adults by a needle-free injection system.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Phase I study of a herpes simp ...... needle-free injection system.
@en
type
label
Phase I study of a herpes simp ...... needle-free injection system.
@en
prefLabel
Phase I study of a herpes simp ...... needle-free injection system.
@en
P2093
P2860
P50
P356
P1476
Phase I study of a herpes simp ...... needle-free injection system.
@en
P2093
Ashok Cattamanchi
Christine M Posavad
Jennifer Moses
Richard Ciccarelli
Richard Ginsberg
Terry J Higgins
Yaela Baine
P2860
P304
P356
10.1128/CVI.00167-08
P577
2008-09-10T00:00:00Z